NCT06763302View on ClinicalTrials.gov

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

NANot yet recruitingINTERVENTIONAL

Enrollment

1,220

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions

B Cell Precursor Acute Lymphoblastic LeukemiaPediatricMinimal Residual DiseaseNext Generation Sequencing (NGS)

Interventions

DRUG

Blinatumomab

The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.

All Listed Sponsors

lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER

NCT06763302 - NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL | Biotech Hunter | Biotech Hunter